- Antarctic bacterium TAB5（1）
No data
- Tag Free（1）
No data
- E. coli（1）
No data
- Unconjugated（1）
No data
- RUO（1）
No data
- No（1）
No data
- 500U/$352.00
- 5000U/$2675.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase | Alkaline phosphatase (4U/ul) | Antarctic bacterium TAB5 | E. coli | SDS-PAGE | $352.00 500U |   |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Targeting HIV-1 Env gp140 antibodies | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome | Details |
| PGDM-1400 | PGDM-1400; PGDM1400LS | Phase 2 Clinical | International Aids Vaccine Initiative | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity | Details |
| VIS-513 | VIS-513; Ab-513 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc | Dengue | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tecovirimat | SIGA-246; ST-246 | Approved | Siga Technologies Inc | Tpoxx | United States | Smallpox | Siga Technologies Inc | 2018-07-13 | Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox | Details |
